비교리스트

 카트 문의
시장보고서
상품코드
1605794

세계의 무균 주사제 수탁생산 시장, 규모, 점유율, 동향, 산업 분석 보고서 : 분자 유형별, 치료 용도별, 투여 경로별, 최종 용도별, 지역별 - 시장 예측(2025-2034년)

Sterile Injectable Contract Manufacturing Market Size, Share, Trends, Industry Analysis Report: By Molecule Type, Therapeutic Application, Route of Administration, End Use, and Region - Market Forecast, 2025-2034
발행일: | 리서치사: Polaris Market Research | 페이지 정보: 영문 127 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

Polaris Market Research의 최신 조사에 따르면, 세계 무균 주사제 수탁생산 시장 규모는 2034년까지 503억 8,000만 달러에 달할 것으로 예상됩니다. 이 보고서는 현재 시장 역학에 대한 자세한 통찰력과 미래 시장 성장에 대한 분석을 제공합니다.

무균 주사제 수탁생산 시장은 생물학적 제제 및 복잡한 의약품에 대한 수요 증가에 힘입어 최근 몇 년동안 큰 폭으로 성장하고 있습니다. 헬스케어 산업이 발전함에 따라 첨단 약물 전달 시스템과 고품질 주사제에 대한 요구가 가장 중요하게 대두되고 있습니다. 주사로 투여되는 광범위한 의약품을 포함한 무균 주사제는 종양학, 당뇨병, 백신 등 다양한 치료 분야에서 필수적입니다. 무균 주사제는 빠른 치료 효과와 최소 침습적 치료 옵션에 대한 선호도가 높아짐에 따라 무균 주사제 시장이 성장하고 있습니다. 이 시장은 제형 개발, 충전 및 마무리 작업, 포장 솔루션 등 전문 서비스를 제공하는 다양한 수탁 제조업체가 특징입니다.

이 시장의 성장에 기여하는 주요 요인 중 하나는 만성 질환의 유병률 증가와 고령화 인구 증가로 인해 혁신적인 치료 솔루션이 요구되고 있습니다. 암, 자가면역질환, 감염성 질환 등은 주사 요법을 필요로 하는 경우가 많기 때문에 무균 주사제에 대한 수요가 증가하고 있습니다. 또한, 개인 맞춤형 의료 및 생물학적 제제에 대한 수요가 급증함에 따라 제약사들은 이러한 복잡한 제제 생산을 전문으로 하는 수탁생산(CMO)을 찾게 되었습니다.

무균주사제 수탁생산 시장 보고서 하이라이트

분자 유형별로는 저분자 부문 무균 주사제 수탁생산 시장은 새로운 치료법에 초점을 맞춘 연구 개발이 진행됨에 따라 예측 기간 동안 큰 폭의 성장이 예상됩니다.

고분자 부문은 생물학적 제제와 바이오시밀러의 확산으로 인해 2024년 시장을 장악할 것으로 예상됩니다.

치료 용도별로는 전 세계 암 발병률 증가와 혁신적인 치료법에 대한 수요 증가로 인해 2024년 암 분야가 시장 점유율을 차지할 것으로 예상됩니다.

세계 시장에서 북미는 탄탄한 제약 인프라, 높은 의료비 지출, 기술 혁신 및 R&D에 대한 강한 집중으로 인해 가장 큰 매출 점유율을 차지하고 있습니다.

아시아태평양 시장은 의료 인프라에 대한 투자 증가와 인구 증가로 인해 예측 기간 동안 높은 CAGR을 나타낼 것으로 예상됩니다.

세계 주요 시장 진출 기업으로는 Baxter; Catalent, Inc. Pharmaceuticals; Recipharm AB; Fresenius Kabi AG; Simtra BioPharma Solutions; and Aenova Group. 등이 있습니다.

목차

제1장 서론

제2장 주요 요약

제3장 조사 방법

제4장 세계의 무균 주사제 수탁제조 시장 인사이트

  • 시장 현황
  • 무균 주사제 수탁제조 시장 역학
    • 성장 촉진요인과 기회
    • 성장 억제요인과 과제
  • PESTEL 분석
  • 무균 주사제 수탁제조 시장 동향
  • 밸류체인 분석
  • COVID-19의 영향 분석

제5장 세계의 무균 주사제 수탁제조 시장 : 분자 유형별

  • 주요 조사 결과
  • 서론
  • 소분자
  • 거대분자

제6장 세계의 무균 주사제 수탁제조 시장 : 치료 용도별

  • 주요 조사 결과
  • 서론
  • 암
  • 당뇨병
  • 심혈관질환
  • 중추신경계
  • 감염증
  • 근골격계 장애
  • 항바이러스제
  • 기타

제7장 세계의 무균 주사제 수탁제조 시장 : 투여 경로별

  • 주요 조사 결과
  • 서론
  • 피하(SC)
  • 정맥내(IV)
  • 근육내(IM)
  • 기타

제8장 세계의 무균 주사제 수탁제조 시장 : 최종 용도별

  • 주요 조사 결과
  • 서론
  • 제약회사
  • 바이오의약품 기업
  • 기타

제9장 세계의 무균 주사제 수탁제조 시장 : 지역별

  • 주요 조사 결과
  • 서론
    • 무균 주사제 수탁제조 시장 평가 : 지역, 2020-2034년
  • 북미
    • 북미 : 분자 유형별, 2020-2034년
    • 북미 : 치료 용도별, 2020-2034년
    • 북미 : 투여 경로별, 2020-2034년
    • 북미 : 최종 용도별, 2020-2034년
    • 미국
    • 캐나다
  • 유럽
    • 유럽 : 분자 유형별, 2020-2034년
    • 유럽 : 치료 용도별, 2020-2034년
    • 유럽 : 투여 경로별, 2020-2034년
    • 유럽 : 최종 용도별, 2020-2034년
    • 영국
    • 프랑스
    • 독일
    • 이탈리아
    • 스페인
    • 네덜란드
    • 러시아
    • 기타 유럽
  • 아시아태평양
    • 아시아태평양 : 분자 유형별, 2020-2034년
    • 아시아태평양 : 치료 용도별, 2020년-2034년
    • 아시아태평양 : 투여 경로별, 2020-2034년
    • 아시아태평양 : 최종 용도별, 2020-2034년
    • 중국
    • 인도
    • 말레이시아
    • 일본
    • 인도네시아
    • 한국
    • 호주
    • 기타 아시아태평양
  • 중동 및 아프리카
    • 중동 및 아프리카 : 분자 유형별, 2020-2034년
    • 중동 및 아프리카 : 치료 용도별, 2020-2034년
    • 중동 및 아프리카 : 투여 경로별, 2020-2034년
    • 중동 및 아프리카 : 최종 용도별, 2020-2034년
    • 사우디아라비아
    • 아랍에미리트(UAE)
    • 이스라엘
    • 남아프리카공화국
    • 기타 중동 및 아프리카
  • 라틴아메리카
    • 라틴아메리카 : 분자 유형별, 2020-2034년
    • 라틴아메리카 : 치료 용도별, 2020-2034년
    • 라틴아메리카 : 투여 경로별, 2020-2034년
    • 라틴아메리카 : 최종 용도별, 2020-2034년
    • 멕시코
    • 브라질
    • 아르헨티나
    • 기타 라틴아메리카

제10장 경쟁 구도

  • 확대와 인수 분석
    • 확대
    • 인수
  • 제휴/협업/합의/공개

제11장 기업 개요

  • Baxter
  • Catalent, Inc.
  • Vetter Pharma-Fertigung GmbH & Co. KG
  • NextPharma Technologies
  • Cipla
  • FAMAR Health Care Services
  • Unither Pharmaceuticals
  • Recipharm AB
  • Fresenius Kabi AG
  • Simtra BioPharma Solutions
  • Aenova Group
LSH 24.12.19

The global sterile injectable contract manufacturing market size is expected to reach USD 50.38 billion by 2034, according to a new study by Polaris Market Research. The report "Sterile Injectable Contract Manufacturing Market Size, Share, Trends, Industry Analysis Report: By Molecule Type (Small Molecules and Large Molecules), Therapeutic Application, Route of Administration, End Use, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The sterile injectable contract manufacturing market has seen significant growth in recent years, driven by the rising demand for biologics and complex pharmaceutical formulations. The need for advanced drug delivery systems and high-quality injectable products has become paramount as the healthcare industry evolves. Sterile injectables, which include a wide range of pharmaceuticals administered via injection, are essential in various therapeutic areas, including oncology, diabetes, and vaccines. Sterile injectables have gained traction due to their ability to provide rapid therapeutic effects and the increasing preference for minimally invasive treatment options. The market is characterized by a diverse landscape of contract manufacturers that offer specialized services, including formulation development, fill-finish operations, and packaging solutions.

One of the key factors contributing to the growth of this market is the rising prevalence of chronic diseases and the increasing aging population, which demands innovative treatment solutions. Conditions such as cancer, autoimmune disorders, and infectious diseases often require injectable therapies, thus amplifying the need for sterile injectables. Additionally, the surge in demand for personalized medicine and biologics has prompted pharmaceutical companies to seek contract manufacturing organizations (CMOs) that specialize in the production of these complex formulations.

Sterile Injectable Contract Manufacturing Market Report Highlights

By molecule type, the sterile injectable contract manufacturing market for the small molecules segment is expected to experience substantial growth during the forecast period due to the ongoing research and development activities focused on new therapies.

The large molecules segment dominated the market in 2024 due to the increasing prevalence of biologics and biosimilars

Based on therapeutic application, the cancer segment accounted for a major share of the market in 2024 due to the rising incidence of cancer worldwide and the increasing demand for innovative treatments.

In the global market, North America held the largest revenue share due to robust pharmaceutical infrastructure, high healthcare spending, and a strong focus on innovation and R&D.

The market in Asia Pacific is estimated to register a significant CAGR during the forecast period owing to the increasing investments in healthcare infrastructure and a rising population.

A few global key market players are Baxter; Catalent, Inc.; Vetter Pharma-Fertigung GmbH & Co. KG; NextPharma Technologies; Cipla; FAMAR Health Care Services; Unither Pharmaceuticals; Recipharm AB; Fresenius Kabi AG; Simtra BioPharma Solutions; and Aenova Group.

Polaris Market Research has segmented the sterile injectable contract manufacturing market report on the basis of molecule type, therapeutic application, route of administration, end-use, and region:

By Molecule Type Outlook (Revenue, USD Billion, 2020-2034)

  • Small Molecules
  • Large Molecules

By Therapeutic Application Outlook (Revenue, USD Billion, 2020-2034)

  • Cancer
  • Diabetes
  • Cardiovascular Diseases
  • Central Nervous Systems Diseases
  • Infectious Disorders
  • Musculoskeletal
  • Anti-Viral
  • Others

By Route of Administration Outlook (Revenue, USD Billion, 2020-2034)

  • Subcutaneous (SC)
  • Intravenous (IV)
  • Intramuscular (IM)
  • Others

By End Use Outlook (Revenue, USD Billion, 2020-2034)

  • Pharmaceutical Companies
  • Biopharmaceutical Companies
  • Others

By Regional Outlook (Revenue, USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Molecule Types
    • 3.2.1. Primary Molecule Types
    • 3.2.2. Secondary Molecule Types

4. Global Sterile Injectable Contract Manufacturing Market Insights

  • 4.1. Sterile Injectable Contract Manufacturing Market - Market Snapshot
  • 4.2. Sterile Injectable Contract Manufacturing Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Rising prevalence of chronic illnesses is driving the sterile injectable contract manufacturing market.
      • 4.2.1.2. Increasing advancement in technology is propelling the sterile injectable contract manufacturing market.
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. The stringent regulatory requirements are hampering the global market.
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Sterile Injectable Contract Manufacturing Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Sterile Injectable Contract Manufacturing Market, by Molecule Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
  • 5.3. Small Molecules
    • 5.3.1. Global Sterile Injectable Contract Manufacturing Market, by Small Molecules, by Region, 2020-2034 (USD Billion)
  • 5.4. Large Molecules
    • 5.4.1. Global Sterile Injectable Contract Manufacturing Market, by Large Molecules, by Region, 2020-2034 (USD Billion)

6. Global Sterile Injectable Contract Manufacturing Market, by Therapeutic Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
  • 6.3. Cancer
    • 6.3.1. Global Sterile Injectable Contract Manufacturing Market, by Cancer, by Region, 2020-2034 (USD Billion)
  • 6.4. Diabetes
    • 6.4.1. Global Sterile Injectable Contract Manufacturing Market, by Diabetes, by Region, 2020-2034 (USD Billion)
  • 6.5. Cardiovascular Diseases
    • 6.5.1. Global Sterile Injectable Contract Manufacturing Market, by Cardiovascular Diseases, by Region, 2020-2034 (USD Billion)
  • 6.6. Central Nervous System
    • 6.6.1. Global Sterile Injectable Contract Manufacturing Market, by Central Nervous System, by Region, 2020-2034 (USD Billion)
  • 6.7. Infectious Diseases
    • 6.7.1. Global Sterile Injectable Contract Manufacturing Market, by Infectious Diseases, by Region, 2020-2034 (USD Billion)
  • 6.8. Musculoskeletal
    • 6.8.1. Global Sterile Injectable Contract Manufacturing Market, by Musculoskeletal, by Region, 2020-2034 (USD Billion)
  • 6.9. Anti-Viral
    • 6.9.1. Global Sterile Injectable Contract Manufacturing Market, by Anti-Viral, by Region, 2020-2034 (USD Billion)
  • 6.10. Others
    • 6.10.1. Global Sterile Injectable Contract Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

7. Global Sterile Injectable Contract Manufacturing Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
  • 7.3. Subcutaneous (SC)
    • 7.3.1. Global Sterile Injectable Contract Manufacturing Market, by Subcutaneous (SC), by Region, 2020-2034 (USD Billion)
  • 7.4. Intravenous (IV)
    • 7.4.1. Global Sterile Injectable Contract Manufacturing Market, by Intravenous (IV), by Region, 2020-2034 (USD Billion)
  • 7.5. Intramuscular (IM)
    • 7.5.1. Global Sterile Injectable Contract Manufacturing Market, by Intramuscular (IM), by Region, 2020-2034 (USD Billion)
  • 7.6. Other
    • 7.6.1. Global Sterile Injectable Contract Manufacturing Market, by Other, by Region, 2020-2034 (USD Billion)

8. Global Sterile Injectable Contract Manufacturing Market, by End-use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
  • 8.3. Pharmaceutical Companies
    • 8.3.1. Global Sterile Injectable Contract Manufacturing Market, by Pharmaceutical Companies, by Region, 2020-2034 (USD Billion)
  • 8.4. Biopharmaceutical Companies
    • 8.4.1. Global Sterile Injectable Contract Manufacturing Market, by Biopharmaceutical Companies, by Region, 2020-2034 (USD Billion)
  • 8.5. Others
    • 8.5.1. Global Sterile Injectable Contract Manufacturing Market, by Others, by Region, 2020-2034 (USD Billion)

9. Global Sterile Injectable Contract Manufacturing Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Sterile Injectable Contract Manufacturing Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 9.3. Sterile Injectable Contract Manufacturing Market - North America
    • 9.3.1. North America: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
    • 9.3.2. North America: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
    • 9.3.3. North America: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.3.4. North America: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.3.5. Sterile Injectable Contract Manufacturing Market - US
      • 9.3.5.1. US: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.3.5.2. US: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.3.5.3. US: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.3.5.4. US: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.3.6. Sterile Injectable Contract Manufacturing Market - Canada
      • 9.3.6.1. Canada: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.3.6.2. Canada: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.3.6.3. Canada: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.3.6.4. Canada: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
  • 9.4. Sterile Injectable Contract Manufacturing Market - Europe
    • 9.4.1. Europe: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
    • 9.4.2. Europe: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
    • 9.4.3. Europe: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.4.4. Europe: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.5. Sterile Injectable Contract Manufacturing Market - UK
      • 9.4.5.1. UK: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.5.2. UK: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.5.3. UK: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.5.4. UK: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.6. Sterile Injectable Contract Manufacturing Market - France
      • 9.4.6.1. France: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.6.2. France: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.6.3. France: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.6.4. France: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.7. Sterile Injectable Contract Manufacturing Market - Germany
      • 9.4.7.1. Germany: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.7.2. Germany: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.7.3. Germany: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.7.4. Germany: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.8. Sterile Injectable Contract Manufacturing Market - Italy
      • 9.4.8.1. Italy: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.8.2. Italy: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.8.3. Italy: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.8.4. Italy: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.9. Sterile Injectable Contract Manufacturing Market - Spain
      • 9.4.9.1. Spain: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.9.2. Spain: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.9.3. Spain: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.9.4. Spain: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.10. Sterile Injectable Contract Manufacturing Market - Netherlands
      • 9.4.10.1. Netherlands: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.10.2. Netherlands: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.10.3. Netherlands: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.10.4. Netherlands: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.11. Sterile Injectable Contract Manufacturing Market - Russia
      • 9.4.11.1. Russia: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.11.2. Russia: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.11.3. Russia: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.11.4. Russia: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.4.12. Sterile Injectable Contract Manufacturing Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.4.12.2. Rest of Europe: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.4.12.3. Rest of Europe: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.4.12.4. Rest of Europe: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
  • 9.5. Sterile Injectable Contract Manufacturing Market - Asia Pacific
    • 9.5.1. Asia Pacific: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
    • 9.5.2. Asia Pacific: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
    • 9.5.3. Asia Pacific: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.5.4. Asia Pacific: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.5. Sterile Injectable Contract Manufacturing Market - China
      • 9.5.5.1. China: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.5.2. China: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.5.3. China: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.5.4. China: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.6. Sterile Injectable Contract Manufacturing Market - India
      • 9.5.6.1. India: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.6.2. India: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.6.3. India: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.6.4. India: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.7. Sterile Injectable Contract Manufacturing Market - Malaysia
      • 9.5.7.1. Malaysia: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.7.2. Malaysia: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.7.3. Malaysia: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.7.4. Malaysia: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.8. Sterile Injectable Contract Manufacturing Market - Japan
      • 9.5.8.1. Japan: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.8.2. Japan: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.8.3. Japan: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.8.4. Japan: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.9. Sterile Injectable Contract Manufacturing Market - Indonesia
      • 9.5.9.1. Indonesia: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.9.2. Indonesia: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.9.3. Indonesia: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.9.4. Indonesia: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.10. Sterile Injectable Contract Manufacturing Market - South Korea
      • 9.5.10.1. South Korea: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.10.2. South Korea: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.10.3. South Korea: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.10.4. South Korea: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.11. Sterile Injectable Contract Manufacturing Market - Australia
      • 9.5.11.1. Australia: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.11.2. Australia: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.11.3. Australia: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.11.4. Australia: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.5.12. Sterile Injectable Contract Manufacturing Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.5.12.2. Rest of Asia Pacific: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.5.12.3. Rest of Asia Pacific: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.5.12.4. Rest of Asia Pacific: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
  • 9.6. Sterile Injectable Contract Manufacturing Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
    • 9.6.2. Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
    • 9.6.3. Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.6.4. Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.5. Sterile Injectable Contract Manufacturing Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.6. Sterile Injectable Contract Manufacturing Market - UAE
      • 9.6.6.1. UAE: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.6.6.2. UAE: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.6.6.3. UAE: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.6.4. UAE: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.7. Sterile Injectable Contract Manufacturing Market - Israel
      • 9.6.7.1. Israel: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.6.7.2. Israel: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.6.7.3. Israel: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.7.4. Israel: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.8. Sterile Injectable Contract Manufacturing Market - South Africa
      • 9.6.8.1. South Africa: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.6.8.2. South Africa: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.6.8.3. South Africa: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.8.4. South Africa: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.6.9. Sterile Injectable Contract Manufacturing Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.6.9.2. Rest of Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.6.9.3. Rest of Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.6.9.4. Rest of Middle East & Africa: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
  • 9.7. Sterile Injectable Contract Manufacturing Market - Latin America
    • 9.7.1. Latin America: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
    • 9.7.2. Latin America: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
    • 9.7.3. Latin America: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
    • 9.7.4. Latin America: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.5. Sterile Injectable Contract Manufacturing Market - Mexico
      • 9.7.5.1. Mexico: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.7.5.2. Mexico: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.7.5.3. Mexico: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.5.4. Mexico: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.6. Sterile Injectable Contract Manufacturing Market - Brazil
      • 9.7.6.1. Brazil: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.7.6.2. Brazil: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.7.6.3. Brazil: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.6.4. Brazil: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.7. Sterile Injectable Contract Manufacturing Market - Argentina
      • 9.7.7.1. Argentina: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.7.7.2. Argentina: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.7.7.3. Argentina: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.7.4. Argentina: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)
    • 9.7.8. Sterile Injectable Contract Manufacturing Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Sterile Injectable Contract Manufacturing Market, by Molecule Type, 2020-2034 (USD Billion)
      • 9.7.8.2. Rest of Latin America: Sterile Injectable Contract Manufacturing Market, by Therapeutic Application, 2020-2034 (USD Billion)
      • 9.7.8.3. Rest of Latin America: Sterile Injectable Contract Manufacturing Market, by Route of Administration, 2020-2034 (USD Billion)
      • 9.7.8.4. Rest of Latin America: Sterile Injectable Contract Manufacturing Market, by End-use, 2020-2034 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Baxter
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Catalent, Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Vetter Pharma-Fertigung GmbH & Co. KG
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. NextPharma Technologies
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Cipla
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. FAMAR Health Care Services
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Unither Pharmaceuticals
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Recipharm AB
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Fresenius Kabi AG
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Simtra BioPharma Solutions
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Aenova Group
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제